Welcome to Team Australian @Global Health Exhibition 2025 Riyadh

Australia is a great partner for life sciences. Howard Florey delivered amazing work on Penicillin turning it in a practical medicine. Since then Australia has been at the forefront of medical research with many amazing medical breakthroughs and innovations starting in Australia. Team Australia is showcasing many new innovations and looking for partners to expand access to these worldwide as well as partnership opportunities to our world leading medical research institutes. Australia also leads clinical trials worldwide and has exhibitors here this week showcasing our abilities. Team Australia is wanting to connect with you.
Search by company name, service category, contact name and more...
15 Results found

Top Professional services in MTP Global Health Exhibition 2025

All Categories

Adelaide University

The University of Adelaide is a prestigious institution ranked in the top 100 universities worldwide. As a member of the Group of Eight, it offers undergraduate and postgraduate degrees, preparing students with deep knowledge and real-world skills. The...
Contact person(s):
Visit Profile

Cambium Bio

Singapore
Cambium Bio Limited is a clinical-stage regenerative medicine company based in Sydney, Australia, focusing on developing innovative biologics for ophthalmology and tissue repair applications. Their primary technology leverages human platelet lysate to create a pipeline of novel therapeutics, with a strong focus on ophthalmology.
  • Emerging Biotech
Contact person(s):
Year founded
2007
Visit Profile

CMAX Clinical Research

Australia
CMAX Clinical Research has been a leader in delivering early phase clinical trials for over 30 years, making it one of the most respected clinical trial businesses in Australia. Their modern custom-built facility is equipped with 78 inpatient beds and located opposite Royal Adelaide Hospital and Adelaide’s Bio-Med City, providing ready access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists. As Australia’s longest-operating early phase unit, CMAX conducts successful world-leading research for local and international clients, specialising in a range of early-phase trials and first-time-in-human studies (FTIH).
Contact person(s):
Languages
  • English
Year founded
1993
No of Employees
300-400
Visit Profile

Dr Sophia AI Pty Ltd

Australia
Dr Sophia AI is a pioneering Medtech company, driven by the belief that health is prosperity. We develop inclusive, defensible, accurate, and scalable solutions to treat and prevent illness at population scales.Our core offering is an agentic AI doctor that assesses, diagnoses, and prescribes medicine, integrating lifetime patient medical history, reported symptoms, and regulatory authority guidelines. Dr Sophia AI brings the world's best medical minds directly to you, offering free, 24/7 personalised care in your pocket.
  • Emerging Medtech
Contact person(s):
Languages
  • English
Year founded
2024
No of Employees
6-26
Visit Profile

HA TECH

Australia and 1 other(s)
HA TECH is an Australian company specializing in innovative diagnostic and pharmaceutical solutions for global health challenges. Focused on early detection of infectious diseases such as respiratory illnesses, STIs, mosquito-borne diseases, and cancer, the company aims to enhance diagnosis and treatment. It also develops pharmaceuticals, including short- and long-acting insulin and GLP receptor agonists for obesity. With Australia's largest diagnostic manufacturing capacity—producing 40 million RT-PCR and 10 million rapid antigen test kits monthly—HA TECH is committed to improving healthcare outcomes worldwide through its advanced solutions and manufacturing expertise.
  • Emerging Biotech
Working with:
Contact person(s):
Year founded
2017
No of Employees
27-65
Visit Profile

JustPartnering

Singapore
JustPartnering is a consulting company that specializes in assisting biotech companies and research institutions in partnering their drug, vaccine, biomarker, and technology development programs with multinational pharma, animal health, and biotech companies. We understand the assets and technologies that pharma and biotech companies are looking for and maintain an extensive network of search and evaluation executives at the top 2,000+ companies worldwide. Using this reach, we connect our clients with the right partners, build interest, and support them through deal-making.The JustSpinouts arm of our business helps research institutions explore and operationalise spinout opportunities – building business and development plans and providing interim or fractional management to get companies established and investor-ready. We assist in raising capital too. With decades of experience founding and leading biotech companies and having a hand in guiding more than 50 pharmaceutical assets from the lab to the clinic, the JustPartnering team brings both industry insight and hands-on expertise to every engagement.We are keen to meet with academic institutions and biotech companies who would like to learn about our services, and with investors with which we can share our pipeline of current investment opportunities.
  • Emerging Biotech
Contact person(s):
Languages
  • English
Year founded
2008
No of Employees
6-6
Visit Profile

Lixa

Australia
Breakthrough in antimicrobial resistanceLixa has uncovered a novel mechanism of action that switches bacteria from resistant-state to sensitive, from biofilm to planktonic, and from untreatable to simply treatable with existing antibiotics below clinical break point. We have 2 lead drug candidates, labelled as universal antimicrobial resistance breakers (uARB), in preparation for Phase 2 clinical trials for oral, intravenous and inhaled drug administration routes. The technology is scalable across human health, animal health, crops, consumer products and industrial anti-foul applications, does not require susceptibility diagnostics and underpins a discovery platform for the uARB drug library expansion. By reversing resistance, Lixa aims to move the needle on the AMR crisis by decades.
  • Emerging Biotech
Contact person(s):
Languages
  • English
Year founded
2021
No of Employees
10-15
Visit Profile

Micro-X

Australia and 1 other(s)
Micro-X is an Australian technology company revolutionizing medical and security imaging through innovative cold cathode carbon nanotube X-ray technology.Headquartered in Australia, Micro-X designs and manufactures lightweight, mobile imaging systems that deliver high-performance diagnostics wherever care is needed, from hospitals and ICUs to disaster zones and Defence operations, all based on Micro-X's Nano-Electronic X-ray (NEX) technology.Its portfolio includes the Rover Plus mobile X-ray and pioneering developments such as the portable Head CT for rapid stroke diagnosis, Lung CT and the Full-Body CT (PARADIGM) system in collaboration with ARPA-H.Micro-X also offers Miniature Baggage Scanners (MBS), Checkpoints and Argus X-ray camera to be used in security imaging applications.Driven by a mission to make world-class imaging accessible anywhere, Micro-X combines precision engineering, sustainability and clinical excellence to transform healthcare globally.
  • Emerging Medtech
Working with:
Contact person(s):
Languages
  • English
Year founded
2011
No of Employees
100-150
Visit Profile

MTPConnect

MTPConnect is Australia's Life Sciences Innovation Accelerator – an independent, not-for-profit organisation established by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector.MTPConnect’s focus is taking cutting-edge research from bench to bedside by working collaboratively with all parts of Australia’s medical technology, biotechnology and pharmaceutical sector; from universities and medical research institutes to start-ups and small to medium sized enterprises to listed companies, and governments, policy makers and regulators.MTPConnect designs and delivers accelerator, sector building and workforce programs for Australian Government agencies and state governments. It co-funds cutting edge innovation and research projects, supports expansion of the clinical trials ecosystem, develops workforce commercialisation skills and represents the Australian sector with a strong and independent voice to promote connections to international markets and improve access to global supply chains. MTPConnect operates the industry-led Australian Antimicrobial Resistance Network – AAMRNet – a collaborative network of key stakeholders working together to address the impact of AMR on human health. It seeks to create an accelerator that will back Australian research into new antimicrobial innovations and to secure investment for a pilot subscription fund for novel antimicrobials to ensure Australians have equitable access to the latest life-saving antibiotics. It also has a dedicated Health and Biosecurity team driving development of dual purpose, advanced medical countermeasures and Defence/National Security related technologies.Across MTPConnect’s accelerator programs, more than $152 million has been directly injected into the Australian life sciences sector, supporting nearly 200 innovation projects. Its investments have leveraged more than $1.3 billion in additional industry contributions and flow-on external investment, allowing SMEs to scale-up and create new jobs and new medical products.MTPConnect’s work has seen more than 1,696 new technologies invented or progressed, 374 new products launched and over 746,000 patients treated.
Contact person(s):
Year founded
2015
Visit Profile

MTPConnect South Australia

Australia
MTPConnect in South Australia delivers the Adelaide Life Science Gateway program for the Adelaide Economic Development Agency (AEDA) - to position Adelaide as a global hub for medical technology, biotechnology and pharmaceutical innovation and help to accelerate economic activity in the City of Adelaide.
  • Accelerator
Contact person(s):
Year founded
2022
Visit Profile
View all Companies
Showing 1-10 of 15 results
MTP Global Health Exhibition 2025